Full history for every metric is available with a Kvantra account

Stock profile

IRRAS AB (publ) (IRRAS.ST)

Country: SwedenSector: HealthcareIndustry: Medical - DevicesExchange: STO

Delisted · last close 3 Nov 2023

Current price
0.16 SEK-1.11%
Last close 3 Nov 2023
Benchmarks

Key financial summary

Financials in SEK
201720182019202020212022TTM
Total revenueSEK m12657224043
Operating profitSEK m-168-197
Net profitSEK m-61-139-151-136-136-167-195
EPS reportedSEK-0.52-0.42
Operating cashflow per shareSEK-0.55-0.55
Capex per shareSEK0.010.01
FCF per shareSEK-0.56-0.56
Free cash flowSEK m-179-193
Net debtSEK m-70-13
Book value equitySEK m14643
Book value per shareSEK0.460.05
Number of sharesm320.54794.81
DPS (TTM paid)SEK0.000.00

Financial summary

Financials in SEK
201720182019202020212022TTM
Value
P/E TTMx--
P/B LTMx1.034.22
P/S LTMx3.774.22
P/FCF LTMx-0.84-0.94
EV/EBITDA LTMx-0.59-0.90
EV/Sales LTMx2.203.91
Earnings Yield LTM%-110.40%-324.19%
FCF Yield%-118.80%-106.29%
Quality
ROE%-114.08%-129.31%
ROIC%-110.30%-110.30%
Operating margin%-420.25%-420.25%
Gross margin%20.91%20.91%
FCF/Sales%-448.22%-448.22%
Growth and momentum
EPS Growth YoY%--
Sales Growth YoY%+78.67%+36.45%
Net Income Growth YoY%--
FCF Growth%--
Operating Profit Growth%--
Dividend and capital structure
Dividend Yield%0.00%0.00%
Dividend Growth%0.00%0.00%
Payout Ratio%0.00%0.00%
FCF/Debtx-28.26-1,931.79
Net Debt/EBITDAx0.420.42
EBIT/Net interestx-602.47-602.47
Net debt/market cap%-46.55%-7.21%
Net debt/Equityx-0.48-0.30
Gross debt/equityx0.040.00

Company overview

IRRAS AB (publ), a medical technology company established in 2011 and headquartered in Stockholm, Sweden, is dedicated to developing medical solutions that enhance the lives of critically ill patients globally. The firm specializes in neurocritical care products, aiming to transform patient outcomes and address complexities inherent in current treatment methods. Among its offerings is IRRAflow, an advanced irrigating intracranial drainage system that integrates controlled drainage, automated irrigation, and continuous intracranial pressure (ICP) monitoring, used effectively for treating hemorrhagic strokes and chronic subdural hematoma. Additionally, IRRAS provides the Hummingbird ICP monitoring system, comprising the HICP200 Control Module and various catheters like the H610 for quad ICP monitoring with drainage and the H110 for solo ICP monitoring. These Hummingbird neuromonitoring tools are vital for managing patients with elevated ICP caused by conditions such as traumatic brain injury, subarachnoid hemorrhage, and strokes. The company distributes its products to hospitals through both its direct sales force and a network of strategic distribution partners.

WebsiteN/A
IndustryMedical - Devices
CountrySweden
Trades inSEK

Similar companies

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Delisted · last close 3 Nov 2023

IRRAS AB (publ) (IRRAS.ST)

IRRAS.ST · STO · Healthcare
0.16 SEK-1.11%
Benchmarks
Financialsin SEK
20212022TTM
About

IRRAS AB (publ), a medical technology company established in 2011 and headquartered in Stockholm, Sweden, is dedicated to developing medical solutions that enhance the lives of critically ill patients globally. The firm specializes in neurocritical care products, aiming to transform patient outcomes and address complexities inherent in current treatment methods. Among its offerings is IRRAflow, an advanced irrigating intracranial drainage system that integrates controlled drainage, automated irrigation, and continuous intracranial pressure (ICP) monitoring, used effectively for treating hemorrhagic strokes and chronic subdural hematoma. Additionally, IRRAS provides the Hummingbird ICP monitoring system, comprising the HICP200 Control Module and various catheters like the H610 for quad ICP monitoring with drainage and the H110 for solo ICP monitoring. These Hummingbird neuromonitoring tools are vital for managing patients with elevated ICP caused by conditions such as traumatic brain injury, subarachnoid hemorrhage, and strokes. The company distributes its products to hospitals through both its direct sales force and a network of strategic distribution partners.

IndustryMedical - Devices
CountrySweden
Trades inSEK

For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.

Unlock all fundamental data

Sign up for Free

Unlock all fundamental data

Sign up for Free